What is GHK-Cu?

GHK is a naturally occurring tripeptide, glycyl-L-histidyl-L-lysine, found in human plasma, saliva, and urine. It was originally isolated in 1973 by Loren Pickart as an activity in human albumin that made older human liver tissue synthesize proteins more like younger tissue. [9]

GHK binds strongly to copper(II), which is why the copper complex GHK-Cu is usually treated as its active tissue form. In skin and wound-repair research, review literature describes GHK-Cu as a remodeling signal: it appears to influence fibroblasts and other repair cells involved in collagen production, water-binding glycosaminoglycans, rebuilding the extracellular matrix, and repair-related gene activity. [9][3][4][5][11]

In casual skincare and peptide discussions, GHK and GHK-Cu are often used as if they mean the same thing. More precisely, GHK is the bare Gly-His-Lys tripeptide, while GHK-Cu is the copper-chelated complex. Product and ingredient labels may also use names such as copper peptide, copper tripeptide-1, Cu-GHK, or Gly-His-Lys-Cu. [9]

Interest in GHK-Cu also comes from its natural decline with age. A skin-regeneration review reports plasma GHK around 200 ng/mL at age 20 and about 80 ng/mL by age 60. That decline helps explain the interest in replenishment-focused skin and repair research, but it does not prove that every GHK-Cu route or product reverses aging. [9][25]

What GHK-Cu is investigated for

GHK-Cu evidence is grouped by practical use case and topical and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

Skin appearance and texture

Topical

65% Moderate

It is reasonable to describe topical GHK-Cu as one of the better-supported cosmetic peptides for skin appearance and matrix-support research. Product-level guarantees should still be avoided because delivery, concentration, and formulation vary. [5][16][6][3][8]

Human evidence

Human evidence includes cosmetic and dermatology reviews plus one small randomized post-CO2-laser study with 13 completed patients. In that study, objective redness, wrinkle, and overall skin-quality measures were not better than control, while patient-reported overall skin-quality improvement was higher with GHK-Cu skincare. [5][6]

Animal / mechanistic evidence

Fibroblast, glycosaminoglycan, tissue-remodeling, delivery, and anti-wrinkle literature support a coherent explanation for how GHK-Cu could affect the skin matrix, especially when the formula can deliver the peptide to living skin layers. [3][4][5][16][15]

Acute wound repair

Topical

49% Preliminary

Topical wound-healing use is a legitimate research area and should be described as under investigation until the Phase 2 trial or comparable human wound studies report results. [19][10]

Human evidence

ClinicalTrials.gov lists a recruiting Phase 2, randomized, double-blind, vehicle-controlled split-wound study in an estimated 60 healthy adults. The study uses 0.1% w/w topical GHK-Cu gel once daily for 14 days, and no results are posted. [19]

Animal / mechanistic evidence

Repair-biology reviews and a mouse scald-wound study support wound-healing research interest, including faster healing with GHK-Cu liposomes than comparator conditions. Animal wound findings still do not establish human clinical effectiveness. [5][10]

Hair and scalp support

Topical

35% Preliminary

Hair and scalp claims can be presented as emerging mechanism-based interest, not as a supported hair-loss treatment. [5][9]

Human evidence

No GHK-Cu-specific controlled human hair-growth outcome source is included.

Animal / mechanistic evidence

Reviews discuss hair follicles, follicle size, and repair biology, but that is not enough to support GHK-Cu as a validated clinical hair-growth treatment. [5][9]

Cellular anti-aging and systemic repair claims

Injectable

10% Insufficient

Available sources do not establish injectable GHK-Cu for systemic repair or anti-aging outcomes. Injectable use should be treated separately from topical cosmetic use and topical wound research. [25]

Human evidence

FDA describes limited human safety data for compounded injectable drugs containing GHK-Cu. [25]

Animal / mechanistic evidence

Preclinical and review literature supports broad repair biology, but it does not establish systemic injectable safety, dosing, or effectiveness in humans. [5][11][25]

Evidence snapshot

Overall confidence

Moderate

65%

GHK-Cu is best supported as a skin and repair-biology peptide. Lab, animal, formulation, and review literature consistently point toward matrix remodeling and wound-repair signaling. The weaker point is direct human outcomes: published human data are still small, topical-focused, and not enough to establish injectable or systemic benefits. [3][5][6][25]

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

45%

Human evidence

Emerging

Human data are still limited: reviews, one small post-CO2-laser study, and a recruiting topical wound trial. This supports topical research interest, not a settled clinical effect size. [5][6][19]

82%

Animal / preclinical

Strong

Preclinical support is stronger than human evidence. Cell, animal, and formulation studies support collagen, matrix repair, skin delivery, and wound-healing biology. [3][4][5][10][8]

88%

Mechanism support

Strong

The mechanism story is one of GHK-Cu's stronger areas. Reviews link it with collagen, water-binding matrix molecules, tissue remodeling, and repair-related gene activity. [3][4][5][11]

Forms & administration

GHK-Cu is most commonly seen in topical cosmetic products and investigational topical gels. Specialized delivery systems, such as liposomes and microneedle-assisted delivery, are studied because skin penetration depends heavily on formulation. GHK-Cu is also discussed in compounded injectable peptide settings, but injectable safety, dosing, and efficacy are much less standardized. [22][19][15][8][25]

TopicalInjectable

Dosing & protocols

The notes below separate published trial design from commonly discussed cosmetic or compounded-use patterns. They are educational context only, not a prescription or product instruction.

Typical Range

Common topical cosmetic range is 1-3% in serums and creams, with some professional-style products described up to about 5%. Compounded injectable protocol patterns commonly fall around 1-2 mg per dose. Concentration, route, and formulation matter. [16][25]

Frequency

Topical cosmetic use is commonly once or twice daily, usually after cleansing and before heavier moisturizers or occlusive layers. Injectable-style protocols are commonly discussed as 1-2x daily, often morning or evening for consistency. The injectable cadence reflects common peptide-protocol patterns rather than established human trial dosing. [6][25]

Timing Considerations

GHK-Cu is commonly scheduled by consistency rather than a strict clock. Topical routines usually stay in the same skin-care step each day, while injectable-style schedules are often anchored to morning or evening. Timing is not tied to meals, exercise, or a specific time of day. [6][25]

Cycle Length

Topical GHK-Cu is usually treated as a maintenance cosmetic active, with visible skin routines commonly assessed over 8-12 weeks. Injectable-style protocols are commonly organized as 4-12 week blocks before reassessment. Cycling logic is mostly practical and empirical, not proven by controlled GHK-Cu protocol trials. [6][25]

Protocol Notes

Topical performance depends heavily on formulation and skin delivery. GHK-Cu is small for a peptide, but passive delivery through the stratum corneum, the outer skin barrier, is still vehicle-dependent. That is why liposomes, penetration enhancers, and microneedle delivery remain active research areas. Copper-peptide products should not be treated as interchangeable: actual peptide content, copper loading, pH, delivery vehicle, and layering with strong low-pH actives can change performance. Injectable GHK-Cu is less standardized, and compounded-product purity, actual peptide content, serum copper status, and ceruloplasmin status raise questions that topical use does not. [15][8][25][27]

What to expect

First 1-2 weeks

Surface-level comfort: smoother feel, better hydration, and calmer-looking skin as the routine settles in. [16][9]

Weeks 4-8

Visible gradual texture and tone improvements, softer-looking fine lines, and a more even post-procedure appearance. [6][16]

Weeks 8-12

Clearest before-and-after comparison of texture, barrier feel, and overall skin smoothness, with continued use functioning more like maintenance. [5][9][16]

After stopping

Fading surface hydration and barrier-feel improvements as the topical routine is removed, with deeper cosmetic effects softening gradually through normal skin turnover and changes in the rest of the skincare routine. [16][6]

Safety profile

Topical cosmetic GHK-Cu is mainly a local-tolerance question: irritation, stinging, redness, itching, or sensitivity. Injectable or systemic GHK-Cu is a different safety category because FDA flags limited human safety data and immunogenicity concerns for compounded injectable products; copper-handling disorders add another systemic caution. [22][25][19][27]

Common side effects

Irritation / redness / stinging [6][8]
Injectable safety uncertainty [25]

Cautions

Copper-handling disorders (systemic) [27]
Injectable purity and immunogenicity [25]

What we don't know

The unresolved safety questions are long-term injectable exposure, controlled human dose-ranging, route-specific interactions, and product purity. For topical products, uncertainty is mostly formulation-level: vehicle, pH, delivery method, copper loading, and actual peptide content can change tolerability and performance. [15][8][25]

Who GHK-Cu is not for

Route-specific avoid and medical-review notes:

Copper-handling disorders
Systemic or injectable GHK-Cu is not a fit for people with Wilson disease or other copper-handling disorders unless a qualified clinician specifically reviews it. Wilson disease prevents the body from removing extra copper, so copper-containing systemic exposure needs separate medical review. [27][25]
Pregnancy or breastfeeding (systemic use)
Pregnancy or breastfeeding is a medical-review situation for systemic or injectable GHK-Cu because human safety data for that route are not established. [25]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Theoretical interactions

Copper-control or copper-removal treatment
Anyone being treated to lower or control copper burden should treat systemic GHK-Cu as a clinician-review interaction. This is not a proven drug-drug interaction; it is a theoretical copper-burden concern because GHK-Cu is a copper-containing peptide. [27]

Pairing notes

Works well with

Hyaluronic acid Topical

A fibroblast and ex-vivo skin study reported that GHK-Cu plus low-molecular-weight hyaluronic acid increased collagen IV measures. This supports a preclinical topical-formulation relationship, not a proven clinical outcome. [13]

Commonly included in these stacks

GLOW Stack

GLOW is a three-component recovery and skin-matrix stack built around BPC-157, TB-500, and GHK-Cu. It is used to frame soft-tissue repair, cell migration, collagen and extracellular-matrix remodeling, and post-procedure skin-support discussions.

BPC-157TB-500GHK-Cu

KLOW Stack

KLOW is a four-component recovery, skin, and inflammation-support stack built around BPC-157, TB-500, GHK-Cu, and KPV. It is used to frame tissue repair, cell migration, skin-matrix remodeling, gut or barrier inflammation, and post-procedure support in one plan.

BPC-157TB-500GHK-CuKPV

GHK-Cu / KPV

GHK-Cu / KPV is a two-peptide skin, barrier, and inflammation-support stack. GHK-Cu supplies the collagen, fibroblast, and matrix-remodeling rationale, while KPV supplies the alpha-MSH-derived anti-inflammatory rationale.

GHK-CuKPV

Not recommended with

Additional copper peptides or copper complexes Topical, Injectable

Avoid treating multiple copper-peptide or copper-complex products as automatically interchangeable or additive. Copper exposure, product stability, route, and formulation need separate review. [27][25]

Regulatory status

United States

United States: not approved for human use as a drug. Cosmetic-only topical use is separate from therapeutic claims. In 503A materials, non-injectable GHK-Cu is under evaluation; injectable GHK-Cu is listed separately for safety-risk concerns. [20][21][22][23][25]

Route	FDA drug approval	503A compounding
Topical	Not Approved Not approved for human use as a drug. Cosmetic-only topical products are separate; wound-healing or disease-treatment claims are drug claims. [20][21][22]	Under Review Non-injectable GHK-Cu is in FDA 503A Category 1: under evaluation, not approved. PCAC consultation is expected before February 2027. [23][24]
Injectable	Not Approved Not approved for human use as an injectable drug. Compounded or research-market availability is not FDA approval. [20][21]	Flagged Injectable GHK-Cu appears in FDA safety-risk materials, with concerns about immunogenicity, aggregation or impurities, and limited human safety data. [25]

Topical

FDA drug approval

Not Approved

Not approved for human use as a drug. Cosmetic-only topical products are separate; wound-healing or disease-treatment claims are drug claims. [20][21][22]

503A compounding

Under Review

Non-injectable GHK-Cu is in FDA 503A Category 1: under evaluation, not approved. PCAC consultation is expected before February 2027. [23][24]

Injectable

FDA drug approval

Not Approved

Not approved for human use as an injectable drug. Compounded or research-market availability is not FDA approval. [20][21]

503A compounding

Flagged

Injectable GHK-Cu appears in FDA safety-risk materials, with concerns about immunogenicity, aggregation or impurities, and limited human safety data. [25]

International

International status is market-, route-, and claim-specific. EU/Europe and the UK use cosmetic notification/responsible-person frameworks; Canada uses cosmetic safety and notification rules; Australia treats therapeutic claims as therapeutic goods. No GHK-Cu-specific market exception is listed for these reviewed markets. [28][29][30][31]

Sports & competition

Topical cosmetic GHK-Cu has no specific anti-doping issue in the reviewed materials. Systemic or injectable use is not athlete-cleared; WADA's non-approved-substances category may be relevant because GHK-Cu is not approved for human use as a drug. [26][20][21]

How it works

GHK-Cu is mainly discussed for slower skin-remodeling and repair biology, not for an instant cosmetic feel. It is a small copper-binding peptide complex studied for how it affects repair signaling around skin cells. The practical story starts with fibroblasts, the cells that help build and remodel collagen and other matrix components. [9][3][4][5]

Much of the evidence points toward extracellular-matrix remodeling. In plain terms, GHK-Cu appears to influence the scaffold around cells: collagen for structure, glycosaminoglycans for water-binding support, and remodeling enzymes that break down and rebuild matrix. That is why claims around texture, firmness, procedure recovery, and wound biology take weeks and depend heavily on delivery. [3][4][5][10][8]

Delivery is the route-specific bottleneck. Topical products must move through the stratum corneum, and studies of liposomes, microneedles, and other systems exist because passive penetration is limited. Injectable or systemic use bypasses that skin barrier, but it also enters a less-supported safety and dosing category. [15][8][14][25]

Gene-expression and anti-aging reviews widen the biological story, but they should not be read as direct clinical proof. The stronger claim is local skin and repair biology; broader systemic anti-aging, injury-recovery, or hair-growth outcomes remain unproven in humans. [11][12][25]

Research gaps & open questions

What the current literature has not yet settled about GHK-Cu:

Which topical formulas perform best in people is still unsettled. The field needs controlled trials comparing concentrations, vehicles, and delivery systems against meaningful skin, scar, wrinkle, and wound endpoints. [16][6][19]

Injectable or systemic GHK-Cu still lacks the basics needed for confidence: human dose-ranging, pharmacokinetics, long-term safety, impurity controls, and route-specific outcome trials. [25]

Product interchangeability is an open question. A copper-peptide serum, liposomal product, microneedle-assisted system, wound gel, and injectable compound should not be assumed to deliver the same exposure or effects. [15][8]

Hair and scalp claims need GHK-Cu-specific controlled human outcome studies before they can be treated as more than mechanism-based interest. [5][9]

Common questions

Is GHK-Cu the same thing as GHK?

They are related, but not identical. GHK is the bare glycyl-L-histidyl-L-lysine tripeptide; GHK-Cu is the copper-bound complex. Skincare sources often use the names loosely, but the copper complex is the form most often discussed for skin remodeling and repair. [9]

What is GHK-Cu best known for?

GHK-Cu is best known for topical skin remodeling, collagen and matrix biology, procedure-recovery research, and wound-repair biology. The strongest support is mechanism, review, and preclinical evidence, with more limited topical human outcome data. [9][3][6]

Does topical GHK-Cu evidence support injectable use?

No. Topical GHK-Cu evidence does not carry over to injections. FDA lists injectable GHK-Cu separately in safety-risk materials, citing potential immunogenicity and limited human safety data. [25]

Is GHK-Cu FDA-approved?

Not approved for human use as a drug. Topical cosmetics are a separate regulatory category, and current 503A compounding materials distinguish non-injectable GHK-Cu from injectable GHK-Cu. [20][21][22][23][25]

Is GHK-Cu supported for hair growth?

Not yet as a validated hair-loss treatment. Reviews discuss follicle-related biology, but the reviewed set does not include a controlled GHK-Cu human hair-growth outcome study. [5][9]

Myths & misconceptions

Myth

Because GHK-Cu affects gene-expression pathways, it is proven as a systemic anti-aging therapy.

Reality

Gene-expression data show pathways worth studying. They do not prove that injectable or systemic GHK-Cu slows aging or improves whole-body outcomes in humans. [11][25]

Myth

Topical cosmetic use and injectable use have the same evidence and risk profile.

Reality

Topical cosmetic use stays mostly in local-skin and formulation questions. Injectable use creates different exposure, product-quality, immunogenicity, dosing, and regulatory questions. [22][25]

Myth

All copper peptide products are basically the same.

Reality

Copper-peptide products can differ in peptide form, copper loading, pH, vehicle, encapsulation, and delivery method. Evidence for one formula should not be copied to all copper-peptide products. [15][8]

History & discovery

GHK-Cu's history begins with GHK, the naturally occurring Gly-His-Lys tripeptide isolated by Loren Pickart in the 1970s during work on why young plasma appeared to restore more youthful protein-synthesis patterns in older liver tissue. The copper complex later became the form most associated with collagen, glycosaminoglycans, extracellular-matrix remodeling, cosmetic skin use, and repair-biology research. [1][2][5][9]

GHK entered the literature as a plasma-derived signal that appeared to change protein synthesis and cell behavior, not as a conventional approved drug. That origin matters because later GHK-Cu interest grew from endogenous repair signaling and cell biology. [1][2]

The copper-bound form became central as fibroblast studies reported effects on collagen and sulfated glycosaminoglycan synthesis. Those findings moved GHK-Cu into skin-matrix, wound-repair, and tissue-remodeling research. [2][3][4]

The modern story is route-specific. Topical cosmetic and investigational wound uses sit in a different evidence and regulatory bucket from injectable or systemic use. Current U.S. compounding materials keep that distinction visible by treating non-injectable GHK-Cu separately from injectable GHK-Cu safety-risk concerns. [9][23][25]

Published research 19 studies

[1]

The use of glycylhistidyllysine in culture systems.

PubMed / In Vitro, 1981. review.

[2]

Growth-modulating tripeptide (glycylhistidyllysine): association with copper and iron in plasma, and stimulation of adhesiveness and growth of hepatoma cells in culture by tripeptide-metal ion complexes.

PubMed / Journal of Cellular Physiology, 1980. in vitro.

[3]

Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+.

PubMed / FEBS Letters, 1988. in vitro.

[4]

Stimulation of sulfated glycosaminoglycan synthesis by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+.

PubMed / Life Sciences, 1992. in vitro.

[5]

The human tri-peptide GHK and tissue remodeling.

PubMed / Journal of Biomaterials Science, Polymer Edition, 2008. review.

[6]

Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin.

PubMed / Archives of Facial Plastic Surgery, 2006. human clinical.

[7]

The effects of topical tripeptide copper complex and helium-neon laser on wound healing in rabbits.

PubMed / Veterinary Dermatology, 2008. animal.

[8]

Microneedle-Mediated Delivery of Copper Peptide Through Skin.

PubMed / Pharmaceutical Research, 2015. ex vivo.

[9]

GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration.

PubMed / BioMed Research International, 2015. review.

[10]

GHK-Cu-liposomes accelerate scald wound healing in mice by promoting cell proliferation and angiogenesis.

PubMed / Wound Repair and Regeneration, 2017. animal.

[11]

Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.

PubMed / International Journal of Molecular Sciences, 2018. review.

[12]

The potential of GHK as an anti-aging peptide.

PubMed / Aging Pathobiology and Therapeutics, 2020. review.

[13]

Synergy of GHK-Cu and hyaluronic acid on collagen IV upregulation via fibroblast and ex-vivo skin tests.

PubMed / Journal of Cosmetic Dermatology, 2023. ex vivo.

[14]

Liposomes as Carriers of GHK-Cu Tripeptide for Cosmetic Application.

PubMed / Pharmaceutics, 2023. review.

[15]

Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes?

PubMed / Molecules, 2025. review.

[16]

Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective.

PubMed / BioImpacts, 2025. review.

[17]

Dimeric copper peptide incorporated hydrogel for promoting diabetic wound healing.

PubMed / Nature Communications, 2025. animal.

[18]

Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.

PubMed / Frontiers in Aging, 2026. review.

[19]

Topical GHK-Cu Gel for Acute Skin Wound Healing

ClinicalTrials.gov, 2026. clinical trial registry.